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2003-2004	 Sxq170	 Sxq200	 A+B	

















































































































































































































Age,	years	 20-39	 10,696	 40	 0.37	
	 40-49	 5,309	 111	 2.09	
	 50-59	 4,649	 134	 2.88	
Race	 Non-Hispanic	black	 4397	 99	 2.25	
	 Other	races	 16,257	 186	 1.14	













































Ever	smoked	 Yes	 8,911	 246	 2.76	
	 No	 11,734	 39	 0.33	
Alcohol	 Yes	 7,708	 132	 1.71	
	 No	 9,239	 78	 0.84	
Evermarijuana	 Yes	 8,424	 188	 2.23	
	 No	 7,079	 28	 0.40	
Evercocaine	 Yes	 2,837	 142	 5.01	
	 No	 12,651	 70	 0.55	
Evermethamphetamine	 Yes	 1,130	 81	 7.17	
	 No	 14,359	 133	 0.93	
Everheroin	 Yes	 391	 71	 18.16	
	 No	 15,095	 142	 0.94	
Everinject	 Yes	 410	 124	 30.24	
	 No	 17,744	 126	 0.71	
Blood	transfusion	 Yes	 4,170	 103	 2.47	
	 No	 19,017	 227	 1.19	
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Lifetime	sex-partners	 0-1	 2,588	 7	 0.27	
	 2	to	9	 7,299	 60	 0.82	
	 >/=10	 5,066	 133	 2.63	
Substance	abuse	risk	
factors	






































	 OR	 95%	CI	 OR	 95%	CI	
Age	at	interview	 	 	 	 	
20-39	y	 (ref)	 (ref)	 (ref)	 (ref)	
40-49	y	 5.8	 2.9-11.5	 7.9	 3.8-16.2	
50-59	y	 5.9	 3.0-11.9	 8.0	 3.5-18.2	
Sex	 	 	 	 	
Male	 2.8	 1.6-4.9	 2.3	 0.9-5.5	
Female	 (ref)	 (ref)	 (ref)	 (ref)	
Race/ethnicity	 	 	 	 	
Non-Hispanic	Black	 2.4	 1.5-3.8	 2.4	 1.3-4.1	
Other	races	 (ref)	 (ref)	 (ref)	 (ref)	
Marital	 	 	 	 	
Married,	living	with	partner	 (ref)	 (ref)	 (ref)	 (ref)	
Sep/Div/Wid/Liv	Sep	 2.7	 1.5-4.7	 1	 0.4-2.1	
Never	married	 1.2	 0.7-2.3	 1.2	 0.5-2.7	
Highest	education	level	 	 	 	 	
Less	than	high	school/GED	 4.6	 3.0-7.1	 2.6	 1.5-4.8	
High	school	or	more	 (ref)	 (ref)	 (ref)	 (ref)	
Family	income	 	 	 	 	
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<	2.0	times	poverty	level	 4.6	 2.8-7.8	 3.5	 1.9-6.6	
>=	2.0	times	poverty	level	 (ref)	 (ref)	 (ref)	 (ref)	
Smoking	 	 	 	 	
Yes	 6.7	 3.5-12.9	 1.9	 0.8-4.2	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Alcohol	Consumption	 	 	 	 	
Yes	 2.1	 1.3-3.3	 1.3	 0.7-2.3	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Marijuana	 	 	 	 	
Yes	 3.6	 2.0-6.6	 0.7	 0.3-1.9	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Cocaine	 	 	 	 	
Yes	 10.5	 6.3-17.6	 1.8	 0.9-3.7	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Heroin	 	 	 	 	
Yes	 28.7	 18.0-45.7	 2.3	 1.1-4.6	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Methamphetamine	 	 	 	 	
Yes	 12	 7.2-20.0	 1.9	 0.8-4.5	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Injection	drugs	 	 	 	 	
Yes	 46	 29.3-72	 8.1	 3.1-21	






















Blood	transfusion	 	 	 	 	
Yes	 2.9	 1.7-5.0	 2.9	 1.4-5.7	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Lifetime	sex-partners	 	 	 	 	
0-1	 (ref)	 (ref)	 (ref)	 (ref)	
2-9	 4.4	 1.5-13	 2.8	 0.9-8.5	























OR	 95%	CI	 OR	 95%	CI	
Low	(0-1)	 (ref)	 (ref)	 (ref)	 (ref)	
Moderate	(2-4)	 4.5	 2.1-9.54	 2.5	 1.1-5.5	
































	 OR	 95%	CI	 OR	 95%	CI	
Age	at	interview	 	 	 	 	
20-39	y	 (ref)	 (ref)	 (ref)	 (ref)	
40-49	y	 5.8	 2.9-11.5	 7.5	 3.5-15.9	
50-59	y	 6	 3.0-11.9	 8.7	 4.2-18	
Sex	 	 	 	 	
Male	 2.8	 1.7-4.9	 3.1	 1.5-6.4	
Female	 (ref)	 (ref)	 (ref)	 (ref)	
Race/ethnicity	 	 	 	 	
Non-Hispanic	Black	 2.3	 1.5-3.8	 1.8	 1.1-2.9	
Other	races	 (ref)	 (ref)	 (ref)	 (ref)	
Marital	 	 	 	 	
Married,	living	with	
partner	
(ref)	 (ref)	 (ref)	 (ref)	
Sep/Div/Wid/Liv	Sep	 2.7	 1.5-4.7	 1.4	 0.7-2.8	






4.6	 3.0-7.1	 2.2	 1.3-3.8	
High	school	or	more	 (ref)	 (ref)	 (ref)	 (ref)	
Family	Income	 	 	 	 	
<2.0	times	poverty	
level	
4.6	 2.8-7.8	 3.7	 2.0-6.8	
>=	2.0	times	poverty	
level	























Yes	 2.1	 1.3-3.3	 1.7	 1.0-2.9	
No	 (ref)	 (ref)	 (ref)	 (ref)	
Smoking	 	 	 	 	
Yes	 6.7	 3.5-12.9	 3.7	 1.8-7.6	
No	 (ref)	 (ref)	 (ref)	 (ref)	
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CHAPTER	FIVE	
DISCUSSION	AND	CONCLUSIONS	
DISCUSSION	
						The	primary	purpose	of	this	study	was	complex	examination	of	the	NHANES	datasets	from	
2003-2014	to	assess	combination	of	demographical	and	behavioral	risk	factors	associated	with	
CHI	in	the	general	U.S.	population.	The	NHANES	survey	provides	important	information	as	it	
comprises	the	nationally	representative	sample	of	the	US	non-institutionalized	population.	The	
standardization	of	its	methods	allows	for	consistent	and	good	quality	data	collection	(41).	This	
is	the	first	study	of	its	kind	to	use	a	complex	data	set	of	6	cohorts	from	2003	through	2014	for	
examination	of	all	possible	risk	factors	(demographical	+	behavioral)	significantly	associated	
with	CHI	in	the	adult	US	population	20-59	years	of	age	using	3	models.		
					As	of	2014,	we	estimated	1.93	million	CHI	persons	in	the	general	U.S.	population	of	age	20-
59	years	with	a	prevalence	of	0.7%	sampled	by	NHANES.	This	has	slightly	declined	since	2010	
based	on	Denniston	et	al	estimation	of	2.7	million	as	CHI	infected	persons	from	2003-2010	in	
the	general	U.S.	population	(4).	As	indicated	in	their	study,	our	analysis	also	suggests	that	
declining	prevalence	of	CHI	in	the	noninstitutionalized	U.S.	population	may	likely	be	because	of	
increasing	mortality	from	HCV-related	conditions	(42).	This	prevalence	is	an	underestimation	of	
the	true	CHI	population	in	the	US	because	NHANES	does	not	include	high-risk	populations	
including	the	incarcerated,	hemodialysis	patients,	the	homeless	and	people	living	on	Indian	
reservations,	all	active	military	and	U.S.	citizens	living	outside	the	U.S.A.		
						In	this	study,	substance	abuse	risk	factors	such	as	drug	use,	alcohol	consumption	and	
smoking	were	grouped	into	low	(0-1),	moderate	(2-4)	and	high	(5-7)	summary	risk	factor	score	
categories	based	on	the	number	of	risk	factors.	In	the	absence	of	categorization	of	the	
summary	risk	factor	scores,	fewer	number	of	CHI	observations	were	observed	in	each	summary	
risk	factor	score	that	resulted	in	wider	confidence	intervals.	Thus,	categorization	helped	to	
overcome	this	concern.	We	have	estimated	the	prevalence	of	CHI	in	these	categories	and	found	
a	linear	increase	in	CHI	prevalence	with	increasing	number	of	substance	abuse	risk	factors	
(Figure:	3)	with	a	maximum	of	11%	CHI	prevalence	in	persons	pf	the	high	category.	This	is	the	
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first	study	of	its	kind	to	estimate	the	CHI	prevalence	in	persons	associated	with	one	or	more	
substance	abuse	risk	factors.		
						Higher	prevalence	of	CHI	was	seen	in	participants	with	the	following	socio-demographic	
characteristics-	40-59	years,	non-Hispanic	black,	male	sex,	less	than	high	school	education,	
widowed/divorced/separated	and	family	income	less	than	2.0	times	poverty	level	when	
compared	to	their	respective	control	groups	(Table	2).	One	or	more	of	these	observations	were	
also	reported	in	earlier	studies	(4,	28,	41).	The	Centers	for	Disease	Control	and	Prevention	and	
US	Preventive	Services	Task	Force	have	recommended	1-time	HCV	screening	in	persons	born	
between	1945-1965	(43,	44)	which	corresponds	to	age	49-69	in	the	year	2014	and	account	for	
most	of	the	prevalent	HCV	cases.	Table	3	in	this	study	noticeably	shows	that	the	age	groups	40-
49	and	50-59	had	a	prevalence	of	2.09%	and	2.88%	respectively	with	a	total	prevalence	of	
4.97%	contributing	to	93%	of	the	infected	population	in	20-59	years	of	age.	Results	from	our	
study	supports	the	findings	from	earlier	studies	(4,	41).	
						Higher	prevalence	of	CHI	was	seen	in	participants	with	the	following	behavioral	risk	
characteristics-	smoking,	alcohol	consumption,	consumption	of	marijuana,	cocaine,	
methamphetamine,	heroin,	injection	drug	users,	blood	transfusion	recipients	prior	to	1992	and	
>/=10	life	time	sex-partners	when	compared	to	their	respective	referent	groups	(Table	3).	
Denniston		et	al	(4)	in	their	study	have	determined	higher	prevalence	of	CHI	in	participants	of	
age	60	and	older	who	had	received	blood	transfusion	before	1992,	in	injection	drug	users,	and	
with	20-49	life	time	sexual	partners	when	compared	to	their	respective	referent	groups.	Taylor	
et	al	(39)	have	indicated	higher	prevalence	of	CHI	in	participants	who	were	former	drinkers	and	
excessive	current	drinkers	when	compared	to	non-drinkers.	Results	from	these	studies	are	in	
line	with	some	of	the	observations	we	have	seen	in	our	study	although	our	study	is	unique	
because	we	have	estimated	CHI	prevalence	in	population	who	are	smokers,	consumers	of	
heroin,	cocaine	and	methamphetamine	that	have	not	been	determined	in	previous	studies.		
						Knowledge	of	risk	factors	for	CHI	is	important	for	several	reasons	not	limited	to	1).	
Identification	of	at-risk	populations	to	link	to	treatment	and	care	2).	Resource	allocation	for	
prevention	measures	and	3).	To	propose	policy	and	guidelines	for	control	and	prevention	of	
CHI.	This	study	is	the	largest	and	most	comprehensive	so	far	where	the	multivariate	models	
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have	included	the	most	established	confounders.	This	study	is	also	the	first	of	its	kind	to	have	
determined	the	risk	factors	associated	with	CHI	by	three	models.	As	reported	in	a	previous	
study	(4),	the	chronic	HCV	full	model	(Table	4)	elicited	that	age	40-59	years,	non-Hispanic	
blacks,	less	than	high	school/GED,	<	2.0	times	poverty	level	were	significantly	associated	with	
CHI.	Additionally,	the	chronic	HCV	full	model	has	also	established	significant	associations	of	
heroin	consumption,	blood	transfusion	and	>/=10	lifetime	sex-partners	with	CHI	that	have	not	
been	reported	earlier.	IDU	remains	the	strongest	risk	factor	for	CHI	as	reported	earlier	(4)	
however	in	the	earlier	study	IDU	was	combined	with	other	drugs	as	a	risk	factor.	For	IDU	
association	with	CHI,	Denniston	et	al	(4)	have	reported	an	OR	of	8.7	whereas	we	have	reported	
an	OR	of	8.1,	therefore	showing	that	in	both	the	studies	the	OR	in	the	multivariate	model	is	
similar.	Race,	low	socioeconomic	status	and	less	education	were	associated	with	CHI	because	
these	factors	are	often	associated	with	high-risk	behaviors	and	hence	higher	risk	of	infection.		
						Chronic	HCV	risk	factor	model	undoubtedly	shows	that	the	OR	increases	with	increasing	
number	of	risk	factors	in	a	person.	This	is	the	first	study	where	the	number	of	substance	abuse	
risk	factors	(alcohol	consumption,	smoking	and	drug	use)	were	categorized	into	low,	moderate	
and	high-risk	categories	to	determine	the	odds	of	being	positive	for	CHI	(Table	4).	This	data	will	
be	crucial	in	identification	of	the	positively	infected	population,	link	them	to	treatment,	and	
care	before	they	become	susceptible	to	secondary	conditions	such	as	hepatocarcinoma	and	
cirrhosis	thereby	reducing	the	HCV	burden	and	its	associated	healthcare	costs.	Missing	values	in	
the	druq	use	questions	in	NHANES	may	not	be	equally	distributed	between	the	different	socio-
economic	status	(SES)	groups,	which	can	lead	to	the	biases	in	prevalence	estimation	and/or	risk	
factor	estimation.	
						BRFSS	datasets	does	not	contain	questions	on	risk	factor	variables	such	as	drug	use	including	
IDU	and	number	of	lifetime	sex-partners.	We	carried	out	the	third	and	final	model	to	establish	a	
prediction	model	for	the	state	level	estimates	of	CHI	including	only	alcohol	and	smoking	risk	
factor	variables,	which	are	available	in	BRFSS.	In	the	absence	of	other	potential	confounders	
used	in	model	1,	alcohol	consumption	and	smoking	were	significantly	associated	with	CHI	
(Table	6).	The	assumption	that	all	states	have	the	national	level	prevalence	of	CHI	may	yield	
inaccurate	state-specific	estimates	because	risk	of	CHI	more	than	likely	varies	by	state.	
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Therefore,	model	3	is	important	because	it	may	be	duplicated	to	calculate	state	level	estimates	
such	as	BRFSS	datasets	and	to	determine	the	state	level	prevalence	of	CHI.		
						The	values	of	C-statistic	for	the	three	models	in	this	study	were	0.94,	0.92	and	0.88	
respectively.	Such	high	c-statistic	values	indicate	stronger	models	with	higher	predictive	
accuracy	of	CHI	in	persons	with	associated	demographic	and	risk	factor	variables	in	respective	
models.	Even	with	the	limited	number	of	risk	factors	modeled	after	the	BRFSS	datasets,	c-
statistic	is	0.88	indicating	good	prediction	of	the	model.	Thus,	our	data	can	serve	as	validation	
of	the	model	based	on	BRFSS	datasets.	
Our	study	comes	with	several	limitations	as	stated	below,	
1. We	did	not	include	participants	of	ages	>/=	60	years	due	to	the	time	and	resource	
limitations	for	conducting	this	thesis	study.	This	limits	us	from	comparing	the	prevalence	
estimates	and	associations	with	CHI	in	this	age	group	(minus	the	drug	questions	and	life-
time	sex-partner	questions	which	are	not	asked	for	this	population	by	NHANES)	to	the	
results	in	previously	published	studies	(4).		
2. Since	NHANES	does	not	ask	drug	and	lifetime	sex-partner	questions	in	adults	of	age	>/=	
60,	we	do	not	know	the	total	true	estimates	of	CHI	prevalence	and	risk	factor	
associations	in	adults	inclusive	>/=	60	years.	In	future,	it	will	be	useful	to	conduct	similar	
studies	in	the	baby	boomers’	cohort	who	are	49-69	years	of	age	in	2014	because	this	
cohort	by	itself	is	an	important	risk	factor	for	CHI.		
3. We	did	not	present	anti-HCV	data	in	this	study	due	to	the	time	and	resource	limitations	
in	performing	the	thesis	work.	National	level	anti-HCV	prevalence	estimates	and	its	risk	
factor	associations	will	enable	to	understand	the	larger	picture	of	the	CHI	such	as	the	
conversion	of	the	number	of	acute	HCV	cases	into	chronic	HCV	cases.		
4. 	As	mentioned	in	earlier	studies	(4,	29,	41),	results	from	NHANES	data	are	only	
applicable	to	the	non-institutionalized	U.S.	civilian	population,	which	underestimates	
the	true	prevalence	of	CHI	because	of	the	exclusion	of	incarcerated,	homeless	and	
institutionalized	population	in	the	datasets.	Results	from	this	thesis	cannot	be	
extrapolated	to	the	aforementioned	high-risk	groups	for	whom	the	prevalence	of	CHI	is	
likely	to	be	higher.		
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5. Questionnaire	data	is	relied	on	self-reporting	and	therefore	subject	to	recall	bias.	Use	of	
IDU	and	other	drugs,	having	>/=	10	lifetime	sex-partners	are	socially	stigmatized	
activities	which	may	result	in	participants	being	unwilling	to	admit	to	this	behavior	
resulting	in	an	underestimation	of	these	factors	in	CHI	prevalence	and	risk	factor	
associations.		
CONCLUSIONS	
						We	conclude	that	the	estimated	persons	infected	with	CHI	as	of	2014	is	approximately	2.2	
million	in	the	civilian	non-institutionalized	U.S	population	sampled	by	NHANES.	It	has	somewhat	
declined	since	2010	which	may	be	because	of	HCV	related	mortality,	however	the	true	
prevalence	estimates	of	CHI	will	be	significantly	higher	when	incarcerated,	homeless	and	other	
population	excluded	from	NHANES	are	included	in	the	analysis.	Injection	drug	use	continues	to	
be	the	strongest	risk	factor	for	CHI.	Persons	with	two	or	more	substance	abuse	risk	factors	have	
the	highest	odds	of	getting	CHI.	Results	from	this	study	will	be	critical	in	development	of	public	
health	policies	and	guidelines	for	the	identification	of	underappreciated	CHI	population	and	
linking	them	to	appropriate	treatment	and	care.		
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